ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2666

Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort

Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Clinical practice, observation, Outcome measures, quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used to assess health-related quality of life (HR-QOL) in clinical research and pharmacoeconomical studies. RA is a chronic disease associated with pain, fatigue, disability, and functional loss, which can markedly decrease a patients’ quality of life (QOL). Treatment strategies for RA have changed greatly since the introduction of biological DMARDs (bDMARDs). The QOL of RA patients can be evaluated using EQ-5D in daily practice.

We analyzed a clinical database of a large prospective observational cohort of patients with RA. Subclasses with distinct patterns were identified in the Japanese version of EQ-5D in RA patients who received biologics. The  clinical features of patients whose QOL improved after use of biologics in daily practice was then examined.

Methods: Since October 2000, we have established a large observational cohort of RA patients in our institute, the Institute Of Rheumatology, Rheumatoid Arthritis (IORRA). Essentially, all RA patients who attend our clinic are asked every 6 months to answer questionnaires including the EQ-5D, disease activity score 28 (DAS28), and Japanese version of the health assessment questionnaire (J-HAQ). More than 5,000 RA patients are included in the cohort, with 813 patients who received bDMARDs being enrolled in this study. The EQ-5D scores of these 813 patients were recorded biannually for 2.5 years and the latent classes of time trends in EQ-5D score based on posterior probability examined after initiation of bDMARDs. The clinical characteristics of each latent class were then compared.

Results: The 813 patients were classified into 4 classes based on time-related changes in EQ-5D score: Class 1, patients with persistent high score of around 0.9 (n=301); Class 2, patients whose score improved from about 0.7 to 0.9 after use of bDMARDs (n=73); Class 3, patients with a persistent moderate score of around 0.7 (n=348); and Class 4, patients with a persistent low score of under 0.6 in spite of use of bDMARDs (n=166). The patients in Class 2 were younger and had a shorter disease duration (p<0.05), higher DAS28 (p<0.001), lower J-HAQ (p<0.05) and more frequent use of non-steroidal agents (p<0.05) than the patients in Class 3. 

Conclusion: This study suggests that QOL is less likely to improve in patients with RA whose disability and deterioration of QOL has already become established despite the use of bDMARDs. We also determined the clinical features of RA patients whose QOL improved after daily use of biologics.


Disclosure: D. Hoshi, None; E. Tanaka, None; E. Inoue, None; Y. Shimizu, None; N. Sugimoto, None; K. Shidara, None; A. Nakajima, None; S. Momohara, AbbVie, Bristol-Myers-Squibb, Eisai, Mitsubishi-Tanabe, and Takeda., 5; A. Taniguchi, Taketora Holdings Co. LTD, 2,AbbVie, Eisai, Mitsubishi-Tanabe, and Teijin., 5; H. Yamanaka, AbbVie, Asahikasei Pharma, Astellas, Bristol-Myers-Squibb, Chugai, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Janssen, Mitsubishi-Tanabe, MSD, Nippon Kayaku, Pfizer, Santen, Taisho-Toyama, Takeda, and Teijin Pharma., 2,Teijin Pharma, Chugai, Astellas, Bristol-Meyers-Squibb, AbbVie, Daiichi-Sankyo, Nihon-Kayaku, Mitsubishi-Tanabe, Pfizer, Takeda, and UCB., 5.

To cite this abstract in AMA style:

Hoshi D, Tanaka E, Inoue E, Shimizu Y, Sugimoto N, Shidara K, Nakajima A, Momohara S, Taniguchi A, Yamanaka H. Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/trajectories-of-eq-5d-in-ra-patients-treated-with-biologics-using-the-iorra-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trajectories-of-eq-5d-in-ra-patients-treated-with-biologics-using-the-iorra-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology